Little Green Pharma saw sales leap 30% to $25.6 million in the financial year to March 31 with Australian flower sales soaring 72% as the company expanded its global footprint into vibrant new markets.
The company has been able to reflect back on the past 12 months with much satisfaction as a period in which they established their produce as one of the most trusted medicinal brands in Australia and Europe and introduced 16 new products into the market.
In its annual report released today, the company said its teams had established a meaningful foothold across the globe in regions that included the aforementioned as well as Denmark, Germany, the United Kingdom and South Africa.
In the course of events, the company was nominated for numerous Cannabiz 2024 awards including: Best Patient-Focused Initiative, R&D project of the year, Best Education or Engagement Initiative and Company of the Year.
Losses after tax were $8,1 million, but with a focus on expansion and long-term growth, LGP said it was encouraged by sales revenue and a war-chest enabling it to pursue targeted opportunities in a burgeoning market.
Dr Michael Lynch-Bell, LGP Independent Non-Executive Chair, said the company had also been able to maintain an excellent diversity profile with 59% female staff and 40% female board membership.